Archives of neurology · 2006
Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wingerchuk Dean M, Rodriguez Moses
Аннотация
BACKGROUND: Many women with multiple sclerosis (MS) experience transient neurologic symptom worsening and fatigue in conjunction with the menstrual cycle. Aspirin reduces MS fatigue in some patients.
OBJECTIVE: To describe 3 women with MS who experienced stereotypic, temperature-independent neurologic symptoms and diurnal fatigue in the mid-to-late luteal phase of the menstrual cycle. Aspirin treatment prevented the symptoms.
DESIGN AND SETTING: Case series at the Mayo Clinic outpatient MS clinics, Scottsdale, Ariz, and Rochester, Minn.
PATIENTS: Three women with relapsing-remitting MS.
INTERVENTIONS: Body temperature measurement, symptom diary, and oral aspirin.
MAIN OUTCOME MEASURES: Body temperature, Modified Fatigue Impact Scale, and evaluation of neurologic symptoms and signs.
RESULTS: Morning oral body temperature did not differ during symptomatic vs asymptomatic portions of the luteal phase (P = .55). Aspirin (650 mg twice daily) prevented symptoms but did not significantly alter the luteal phase body temperature.
CONCLUSIONS: Aspirin prophylaxis may prevent luteal phase-associated MS pseudoexacerbations. However, the observed relationship between the luteal menstrual phase and MS symptom worsening is not fully explained by thermoregulation, which implicates other hormonal or immunologic mechanisms.
OBJECTIVE: To describe 3 women with MS who experienced stereotypic, temperature-independent neurologic symptoms and diurnal fatigue in the mid-to-late luteal phase of the menstrual cycle. Aspirin treatment prevented the symptoms.
DESIGN AND SETTING: Case series at the Mayo Clinic outpatient MS clinics, Scottsdale, Ariz, and Rochester, Minn.
PATIENTS: Three women with relapsing-remitting MS.
INTERVENTIONS: Body temperature measurement, symptom diary, and oral aspirin.
MAIN OUTCOME MEASURES: Body temperature, Modified Fatigue Impact Scale, and evaluation of neurologic symptoms and signs.
RESULTS: Morning oral body temperature did not differ during symptomatic vs asymptomatic portions of the luteal phase (P = .55). Aspirin (650 mg twice daily) prevented symptoms but did not significantly alter the luteal phase body temperature.
CONCLUSIONS: Aspirin prophylaxis may prevent luteal phase-associated MS pseudoexacerbations. However, the observed relationship between the luteal menstrual phase and MS symptom worsening is not fully explained by thermoregulation, which implicates other hormonal or immunologic mechanisms.